RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Here's a link to the Montreal Conference where Cortex will be presenting next week (4:30 Tuesday). The press release mentioned some animal data on the high impacts for Huntington's and Frag-X, and an update on the non-Ampakine in-license strategy. It would only seem prudent for Cortex to wait until the fate of CX-717 is known (Spring) before committing to an in-licensing deal. Cortex is going to have to be very tight with their money for a while, unless they want a repeat of a $1.50 type financing -

http://www.bmocm.com/conferences/healthcare2006/participating/default.aspx